https://orcid.org/0000-0001-9654-8385
Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Giorgio Lorenzo Colombo, Maria Chiara Valentino, Alessandra Fabi, Maria Vittoria Dieci, Mauro Caruggi, Giacomo Matteo Bruno, Gloria Lombardi & Sergio Di Matteo. (2023) Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy. Therapeutics and Clinical Risk Management 19, pages 301-312.
Read now
Read now
Sarjana Raikwar, Ankit Jain, Shivani Saraf, Pooja Das Bidla, Pritish Kumar Panda, Ankita Tiwari, Amit Verma & Sanjay K. Jain. (2022) Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape. Expert Opinion on Drug Delivery 19:3, pages 247-268.
Read now
Read now
Jiangping Yang, Jiaqi Han, Maolang Tian, Kun Tian, Wenjun Liao & Xi Yan. (2020) Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Cancer Management and Research 12, pages 12905-12913.
Read now
Read now
Articles from other publishers (11)
Dina Hany, Marloes Zoetemelk, Kaushik Bhattacharya, Patrycja Nowak-Sliwinska & Didier Picard. (2023) Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer. Cellular and Molecular Life Sciences 80:3.
Crossref
Crossref
Miyuki Hirabayashi, James K. Chambers, Akiyoshi Tani, Hirotaka Tomiyasu, Tomoki Motegi, Kenji Rimpo, Hiroyuki Nakayama & Kazuyuki Uchida. (2022)
mRNA
sequencing analysis and growth inhibitory effects of palbociclib on cell lines from canine histiocytic proliferative disorders
. Veterinary and Comparative Oncology 20:3, pages 587-601.
Crossref
Crossref
Evita G. Weagel, Jason M. Foulks, Adam Siddiqui & Steven L. Warner. (2022) Molecular glues: enhanced protein-protein interactions and cell proteome editing. Medicinal Chemistry Research 31:7, pages 1068-1087.
Crossref
Crossref
Chiaki Takahashi & Jun-ya Kato. (2022) Targeting Abnormal Cell Cycle in Cancer: A Preface to the Special Issue. Onco 2:1, pages 34-35.
Crossref
Crossref
Harry R Haynes, Vivek Mohan, Behrang Mozayani & Patrick Gallagher. (2021) Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding. The Breast Journal 27:7, pages 612-614.
Crossref
Crossref
Irina V. Kolyadina, Natalia R. Abidova, Arshak A. Akopyan, Galina V. Antonova, Oksana I. Arapova, Elvira A. Bobrova, Larisa V. Bolotina, Chulpan K. Valiakhmetova, Anna V. Vasilevskaya, Lyubov Y. Vladimirova, Mikhail V. Volkonskiy, Inna P. Ganshina, Irina E. Gudkova, Alexandr S. Dergunov, Irina V. Evstigneeva, Viktoria S. Egurenkova, Aleksei V. Emshanov, Lyudmila G. Zhukova, Elena V. Zueva, Elena V. Karabina, James J. Kolokolov, Svetlana V. Kuzmicheva, Olesya A. Kuchevskaya, Ivan A. Luev, Ksenia S. Maistrenko, Elena V. Markizova, Vasily V. Marfutov, Sergey P. Medvedev, Yulia I. Merzlikina, Tatyana A. Nersesova, Elena G. Ovchinnikova, Svetlana A. Orlova, Natalia Y. Samaneva, Olesya A. Stativko, Anna E. Storozhakova, Daniil L. Stroyakovskiy, Alexander V. Sultanbaev, Asiat I. Tekeeva, Natalia V. Fadeeva, Alina N. Fedorova, Oksana M. Shalaeva, Irina A. Shangina, Oksana N. Shirokova, Alisa R. Shumskikh & Mariam Z. Yakubova. (2021) Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice. Journal of Modern Oncology 23:1, pages 68-76.
Crossref
Crossref
Yu Sato, Kensuke Shigeta, Tensei Hirasawa, Toshihiro Sato, Jiro Ogura, Masamitsu Maekawa, Akiko Ebata, Yohei Hamanaka, Hiroshi Tada, Takanori Ishida, Masafumi Kikuchi & Nariyasu Mano. (2021) Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS. Journal of Chromatography B 1173, pages 122655.
Crossref
Crossref
Chiaki Takahashi & Jun-ya Kato. (2021) Synthetic Inhibitors of CDK4/6 Activities and Tumor Suppression: A Preface to the Special Issue. Onco 1:1, pages 1-2.
Crossref
Crossref
I. V. Kolyadina & I. V. Poddubnaya. (2020) ESR1 mutation as potential predictive marker for choice of treatment tactics in hormone-resistant HR+/HER2-negative breast cancer. Medical alphabet:29, pages 68-73.
Crossref
Crossref
Suzanne Bakewell, Isabel Conde, Yassi Fallah, Mathew McCoy, Lu Jin & Ayesha N. Shajahan-Haq. (2020) Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer. Cancers 12:9, pages 2647.
Crossref
Crossref
Irina V. Kolyadina, Inna P. Ganshina, Svetlana V. Kuzmicheva, Asiiat I. Tekeeva, James D. Kolokolov, Mikhail V. Volkonskii & Irina V. Poddubnaya. (2020) Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience. Journal of Modern Oncology 22:2, pages 98-103.
Crossref
Crossref